Coronavirus

Join us tomorrow for an informative discussion on CDC guidance and insights from medical experts on navigating a way back to in-school learning.

Symptomatic case fatality ratio and infection fatality ratio provide a more accurate picture of pandemic, they say.

Citing the rise of the anti-vaccine movement, Peter Hotez, MD, PhD, explains the role scientists can play in building trust and literacy by engaging the public.

Rodney E. Rohde, PhD, a clinical laboratory scientist, helps break down how carefully EUA releases need to be read in order for the public and for scientists from other fields to parse them for useful information.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

The US CDC has been engaged in a back and forth with media for several days after reductionist reporting on immunity related to COVID-19 suggested categorical proof of antibody based immunity to reinfection.

In a small study, preliminary analysis shows patients given this treatment early in hospitalization showed improvement and reduced mortality rates.

Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.

July ended with nearly 100,000 new cases among children in the US. What does that mean for public and school reopenings?

SalivaDirect is unique in that it does not require a particular type of swab or collection device; any sterile container is suitable for saliva collection with the test.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.

The American College of Physicians says it no longer plans to update its rapid, living practice points because it doesn’t believe new evidence will support the use of the antiviral medications in the fight against COVID-19.

Not all COVID-19 test results are accurate, according to scientists. Because false negatives can result in infectious individuals mingling with others, some researchers advocate multiple tests in order to catch cases that have slipped through the cracks.

Two Boston physicians using Interleukin-6 inhibitors report a reduction in intubation and mortality rates.

A committee of experts convened by the National Academies of Sciences, Engineering, and Medicine recently offered recommendations for local school districts to guide decisions about school reopening during the pandemic.

Walter A. Orenstein, MD, answers audience questions collected during our Vaccine Race webinar.

A new survey shows parents’ fears of getting kids to their providers for fear of contracting the virus.

US government has purchased this batch of vaccines, which Moderna will manufacture concurrently with its phase 3 trials.

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

The pharmaceutical industry plays an essential role in advancing antimicrobial stewardship and addressing the growing threat of resistant pathogens.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The modified adenovirus-strain candidate did not reach phase 3 assessment, and was criticized by the WHO for being rushed through assessment.

A backlog in testing in the US can severely impact the ability to perform contact tracing.

The antiviral is currently emergency authorized for treatment of severe COVID-19.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.